GCM
CHRS icon

Ghisallo Capital Management’s Coherus Oncology CHRS Stock Holding History

Ghisallo Capital Management’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-150,000
Closed -$641K – 126
2023
Q2 		$641K Buy
+150,000
New +$885K 0.08% 102

Other funds holding CHRS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
ACB
Aristotle Capital Boston Boston, Massachusetts $1.61B AUM 19.82% 1-Year Est. Return

Ghisallo Capital Management's CHRS Position: Q3 2023 in Review

Ghisallo Capital Management sold out of Coherus Oncology (CHRS) in Q3 2023, closing a stake of 150,000 shares — an estimated $641K sold.

Ghisallo Capital Management first reported a position in CHRS in Q2 2023 and held it in 1 quarter. The position peaked at $641K in Q2 2023. 169 funds tracked by Wall St. Rank hold CHRS as of Q3 2023.

  • Ghisallo Capital Management reported no remaining Coherus Oncology position as of Q3 2023 after selling out during the quarter.
  • Ghisallo Capital Management sold 150,000 Coherus Oncology shares in Q3 2023, an estimated $641K.
  • Ghisallo Capital Management first reported a position in Coherus Oncology in Q2 2023 and held it in 1 quarter.
  • Ghisallo Capital Management's Coherus Oncology position peaked at $641K in Q2 2023.
  • 169 funds tracked by Wall St. Rank held Coherus Oncology as of Q3 2023.

Based on Ghisallo Capital Management's 13F filing for Q3 2023, filed 13 Nov 2023.